Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid

Pemetrexed is a multi-targeted antifolate that inhibits three enzymes used in purine and pyrimidine synthesis — thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). Pemetrexed has been approved by United States Food and Drug Administration (US FDA) in combination with platinum for the treatment of advanced non-squamous non-small cell lung car cinoma (NSCLC) (1) and malignant mesothelioma (2). Studies showed that pemetrexed has equivalent efficacy to docetaxel but is associated with significantly less toxicity (1,3).

Source: Lung Cancer - December 4, 2020 Category: Cancer & Oncology Authors: Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam Source Type: research